These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23687793)

  • 21. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
    Eturi A; Bhasin A; Zarrabi KK; Tester WJ
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of chemotherapy for urothelial tract tumors.
    Sternberg CN; Scher HI
    Oncology (Williston Park); 1987 Jul; 1(5):41-50, 60. PubMed ID: 3079483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
    Mazzola CR; Siddiqui KM; Billia M; Chin J
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical applications for targeted therapy in bladder cancer.
    Adam L; Kassouf W; Dinney CP
    Urol Clin North Am; 2005 May; 32(2):239-46, vii. PubMed ID: 15862621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bladder cancer and new drugs].
    Massard C; Albouy B; Gross-Goupil M; Ravaud A
    Bull Cancer; 2010; 97 Suppl Cancer de la vessie():43-50. PubMed ID: 20534389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel molecular targets for the therapy of urothelial carcinoma.
    Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
    Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapies in urothelial carcinoma.
    Ghosh M; Brancato SJ; Agarwal PK; Apolo AB
    Curr Opin Oncol; 2014 May; 26(3):305-20. PubMed ID: 24685646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
    McCaffrey JA; Herr HW
    Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
    Sonpavde G; Bellmunt J; Rosenberg JE; Regazzi AM; Bajorin DF; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Pond GR
    Clin Genitourin Cancer; 2014 Dec; 12(6):395-8. PubMed ID: 25035282
    [No Abstract]   [Full Text] [Related]  

  • 32. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 35. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
    Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
    Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic chemotherapy of urothelial cancer].
    Wolff JM; Jakse G
    Urologe A; 1992 May; 31(3):W19-24. PubMed ID: 1615589
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer.
    Raghavan D
    Cancer; 2003 Apr; 97(8 Suppl):2083-9. PubMed ID: 12673700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Targeted Therapy for Bladder Cancer.
    Thibault C; Loriot Y
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):585-596. PubMed ID: 33958152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of advanced bladder cancer in the era of targeted therapies.
    Soave A; Engel O; Von Amsberg G; Becker A; Dahlem R; Shariat SF; Fisch M; Rink M
    Minerva Urol Nefrol; 2015 Jun; 67(2):103-15. PubMed ID: 25604695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.